The World Health Organization in its 2019 research survey has stated that in the last decade due to needle stick injury approximately 2 million healthcare professionals experienced percutaneous exposure to infectious diseases such as Hepatitis B and C virus, and HIV.
The pharmaceutical packaging market is expected to witness a CAGR of 10% during the forecast period of 2025 to 2033, driven by various compelling factors, while still facing notable challenges. The pharmaceutical packaging market is thriving due to increased pharmaceutical manufacturing, the growth of contract packaging services, and the focus on sustainable packaging. However, regulatory challenges present hurdles that need to be navigated. The shift toward glass as a preferred packaging material and the growing reliance on contract packaging services are key trends to watch.
Malarial parasites are developing resistance to anti-malarial drugs, therefore conventional treatment for malaria has proven to be less efficacious. Malaria vaccines would curb the growth of malarial cases and help save millions. Development of malaria vaccine has been one of the greatest challenges faced by research institutes and manufacturers.
Sepsis is a potentially life-threatening complication due to presence of both infection and the systemic inflammatory response; it is caused by overwhelming immune response to infection. Sepsis is treated as a medical emergency, and severe case of sepsis may lead to septic shock, in which blood pressure reduces dramatically.
Pain therapeutics are used to relieve pain either by stopping the pain signals or by altering the brain interpretation to these signals. Pain therapeutics have the ability to reduce pain intensity but do not treat the cause of the pain.
Cell cultures are an important and fundamental tool essential for the development of target based therapies such as biosimilars, biologics and personalized medicine. The current trend for developing medication is making it more patient centric thus personalized medicines are in greater demand for treating various chronic conditions and orphan indications. The development of target based therapies for the above-mentioned conditions require to be carried at a faster pace with no scope for errors during the development stages.
Whey protein ingredients are referred to as globular proteins which are extracted from whey, a liquid obtained as a derivative of cheese. Consumers are preferring whey protein ingredients due to their high protein content as compared to egg, soy and other dairy products. Whey proteins are widely consumed in the form of nutritional supplements owing to various health benefits related with them.
Diabetic foot ulcers is a type of chronic wound affecting millions of patients across the globe. Diabetic foot ulcers are thickened wounds below the ankle in a diabetic patient irrespective of its duration. On account of high prevalence of diabetes, increasing geriatric population and lack of awareness on preventive measures the global diabetic foot ulcers market shows a lucrative growth between the forecast period 2025 and 2033.
Natural alternative sweeteners, also known as sugar substitutes are chemicals which are added to some food products to make them taste sweet with presence of little or no calories. The over consumption of sugary foods leads to weight gain, resistance to insulin, type 2 diabetes and fatty liver. Therefore, in a bid to satisfy consumer’s sweet tooth without compromising with the health has led scientists and nutrition professionals to develop healthier natural alternatives to sugar.
Electronic batch record (EBR) refer to software that electronically stores and manages data for a given batch as well as the whole manufacturing process step-by-step. The software uses the existing enterprise resource planning (ERP) system to systematically produce a formal master batch record or electronic batch record. This stores all of the materials, processes and activities that went into producing a given product.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.
